Shanghai MicuRx Pharmaceutical Co. Ltd. A
Shanghai MicuRx Pharmaceutical Co., Ltd., a biopharmaceutical company, discovers, develops, and commercialize drugs for unmet medical needs. It is developing Contezolid (MRX-I) and Contezoilid acefosamil (MRX-4) oxazolidinone antibiotics for multidrug-resistant gram-positive bacteria; MRX-8 MRX, a polymyxin antibiotic, to target multidrug-resistant Gram-negative bacteria; MRX-5 for multidrug-resi… Read more
Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373) - Net Assets
Latest net assets as of June 2025: CN¥313.38 Million CNY
Based on the latest financial reports, Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373) has net assets worth CN¥313.38 Million CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥772.90 Million) and total liabilities (CN¥459.53 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥313.38 Million |
| % of Total Assets | 40.55% |
| Annual Growth Rate | -8.28% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 92.5 |
Shanghai MicuRx Pharmaceutical Co. Ltd. A - Net Assets Trend (2020–2024)
This chart illustrates how Shanghai MicuRx Pharmaceutical Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai MicuRx Pharmaceutical Co. Ltd. A (2020–2024)
The table below shows the annual net assets of Shanghai MicuRx Pharmaceutical Co. Ltd. A from 2020 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥438.96 Million | -47.37% |
| 2023-12-31 | CN¥834.00 Million | -31.32% |
| 2022-12-31 | CN¥1.21 Billion | +177.00% |
| 2021-12-31 | CN¥438.37 Million | -29.32% |
| 2020-12-31 | CN¥620.23 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai MicuRx Pharmaceutical Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 130841460909.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | CN¥2.24 Billion | 511.13% |
| Total Equity | CN¥438.96 Million | 100.00% |
Shanghai MicuRx Pharmaceutical Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai MicuRx Pharmaceutical Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TCI Co Ltd
TWO:8436
|
$317.77 Million |
|
BFI Finance Indonesia Tbk
JK:BFIN
|
$317.78 Million |
|
First Foundation Inc.
NYSE:FFWM
|
$317.81 Million |
|
Everlight Chemical Industrial Corp
TW:1711
|
$317.86 Million |
|
Newron Pharmaceuticals SpA
SW:NWRN
|
$317.49 Million |
|
Southern Sun Limited
F:JK9
|
$317.45 Million |
|
Eco-Shop Marketing Berhad
KLSE:5337
|
$317.39 Million |
|
Ningbo Daye Garden Machinery Co Ltd
SHE:300879
|
$317.38 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai MicuRx Pharmaceutical Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 834,003,193 to 438,963,752, a change of -395,039,441 (-47.4%).
- Net loss of 440,721,217 reduced equity.
- Dividend payments of 6,542,266 reduced retained earnings.
- Other factors increased equity by 52,224,042.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-440.72 Million | -100.4% |
| Dividends Paid | CN¥6.54 Million | -1.49% |
| Other Changes | CN¥52.22 Million | +11.9% |
| Total Change | CN¥- | -47.37% |
Book Value vs Market Value Analysis
This analysis compares Shanghai MicuRx Pharmaceutical Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.81x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 5.00x to 8.81x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2020-12-31 | CN¥1.18 | CN¥5.90 | x |
| 2021-12-31 | CN¥0.83 | CN¥5.90 | x |
| 2022-12-31 | CN¥1.85 | CN¥5.90 | x |
| 2023-12-31 | CN¥1.27 | CN¥5.90 | x |
| 2024-12-31 | CN¥0.67 | CN¥5.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai MicuRx Pharmaceutical Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -100.40%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -338.31%
- • Asset Turnover: 0.15x
- • Equity Multiplier: 1.93x
- Recent ROE (-100.40%) is below the historical average (-46.91%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2020 | -13.92% | 0.00% | 0.00x | 1.09x | CN¥-148.35 Million |
| 2021 | -51.62% | -2953.91% | 0.01x | 1.48x | CN¥-270.11 Million |
| 2022 | -18.14% | -456.99% | 0.03x | 1.23x | CN¥-341.73 Million |
| 2023 | -50.49% | -463.91% | 0.08x | 1.40x | CN¥-504.52 Million |
| 2024 | -100.40% | -338.31% | 0.15x | 1.93x | CN¥-484.62 Million |
Industry Comparison
This section compares Shanghai MicuRx Pharmaceutical Co. Ltd. A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai MicuRx Pharmaceutical Co. Ltd. A (688373) | CN¥313.38 Million | -13.92% | 1.47x | $317.70 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |